For this purpose, 18 T1DM patients with IAH were assigned either into a group performing multiple daily injections (MDIs) with self-monitoring of blood glucose (SMBG), MDIs with SMBG and real-time continuous glucose monitoring (RT-CGM), continuous subcutaneous insulin infusion (CSII) with SMBG, or CSII with SMBG and RT-CGM [22]. The gene discussed is INS; the disease is type 1 diabetes mellitus.